Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 32Carcinoma, Non-Small-Cell Lung 29Leukemia, Myeloid, Acute 27Melanoma 25Neoplasms 22Lymphoma 21Pancreatic Neoplasms 18Multiple Myeloma 18Recurrence 17Lung Neoplasms 17Leukemia 17Ovarian Neoplasms 16Neoplasm Metastasis 15Lymphoma, Non-Hodgkin 15Carcinoma, Hepatocellular 15Colorectal Neoplasms 14Lymphoma, Follicular 13Myelodysplastic Syndromes 12Lymphoma, B-Cell 12Leukemia, Lymphocytic, Chronic, B-Cell 12Burkitt Lymphoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Large B-Cell, Diffuse 11Prostatic Neoplasms 10Lymphoma, Mantle-Cell 10Brain Neoplasms 10Stomach Neoplasms 9Squamous Cell Carcinoma of Head and Neck 9Liver Neoplasms 9Glioma 9

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Withdrawn × Camurati-Engelmann Syndrome × Clear all
NCT04158700 2020-02-19

A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1/2 Withdrawn
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Camurati-Engelmann Syndrome, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡